Akiyode Oluwaranti, Major Jateh, Ojo Abiola
1 Clinical & Administrative Pharmacy Sciences, Howard University College of Pharmacy, Washington, DC, USA.
J Pharm Pract. 2017 Oct;30(5):534-540. doi: 10.1177/0897190016647232. Epub 2016 May 10.
Aflibercept is the most recently approved vascular endothelial growth factor (anti-VEGF) inhibitor for the management of diabetic macular edema and diabetic retinopathy. The purpose of this article is to review the efficacy and safety of aflibercept in the management of diabetic eye complications and to describe its place in therapy. Anti-VEGF agents have been noted in clinical trials to be superior to laser photocoagulation, the standard therapy ( P < .0001, P ≤ .0085, respectively). Aflibercept has been comparatively studied with other anti-VEGF agents, namely, bevacizumab and ranibizumab, and noted to be equally efficacious and safe in patients with mild visual acuity loss ( P > .50). However, in the treatment of patients with diabetic macular edema having moderate to severe visual acuity loss, aflibercept outperformed the other 2 anti-VEGF agents (aflibercept vs bevacizumab, P < .001; aflibercept vs ranibizumab, P = .003). However, additional studies are needed to fully appreciate the long-term safety and efficacy of aflibercept and the anti-VEGF therapy class.
阿柏西普是最近被批准用于治疗糖尿病性黄斑水肿和糖尿病性视网膜病变的血管内皮生长因子（抗VEGF）抑制剂。本文旨在综述阿柏西普治疗糖尿病眼部并发症的疗效和安全性，并描述其在治疗中的地位。在临床试验中已注意到抗VEGF药物优于标准治疗方法激光光凝（分别为P <.0001，P≤.0085）。已将阿柏西普与其他抗VEGF药物（即贝伐单抗和雷珠单抗）进行了对比研究，结果表明在轻度视力丧失患者中阿柏西普同样有效且安全（P>.50）。然而，在治疗中度至重度视力丧失的糖尿病性黄斑水肿患者时，阿柏西普的表现优于其他两种抗VEGF药物（阿柏西普与贝伐单抗相比，P <.001；阿柏西普与雷珠单抗相比，P =.003）。然而，需要进行更多研究以全面了解阿柏西普和抗VEGF治疗类别的长期安全性和疗效。
